logo-loader
RNS
viewProteome Sciences PLC

Notice of Results

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .v{size:595.3pt 841.9pt;margin:56.75pt 72.0pt 1.0cm 72.0pt;}div.v{}p.au{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align: right}span.as{font-size:12.0pt;line-height:115%;font-family:"Times New Roman","serif"}p.av{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}span.aq{font-size:12.0pt;line-height:115%; font-family:"Times New Roman","serif"}p.aw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.ao{font-size:14.0pt;line-height:115%}span.am{font-size:4.0pt;line-height:115%}p.ax{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:13.5pt;text-align:justify;line-height: normal} span.al{font-size:11.5pt}p.ay{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 13.5pt; text-align: justify}p.az{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 13.5pt; text-align: justify; text-autospace: none}table.ba{width:494.7pt;margin-left:-10.8pt;border-collapse:collapse}tr.af{height:15.3pt}td.ag{width:483.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.3pt}span.ah{color:black}td.ad{width:268.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.3pt}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:107%}td.ac{width:204.95pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.3pt} tr.z{height:45.95pt}td.ab{width:268.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:45.95pt}td.aa{width:204.95pt;padding:0cm 5.4pt 0cm 5.4pt; height:45.95pt}a.x{font-weight: bold}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify; text-autospace: none} /**/
RNS Number : 7859S
Proteome Sciences PLC
14 March 2019
 

                                                                                    14 March 2019

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Notice of Results

 

The Directors of Proteome Sciences look forward to updating shareholders on the Company's performance, and on the outlook for 2019, at the time of announcing the 2018 full year results which are scheduled for release on 2 April 2019. 

Annual General Meeting

The Annual General Meeting of the Company will take place at the offices of Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at 2.30pm on 30 April 2019.  Formal notice of such will be posted to shareholders with the annual report in April.

 

For further information please contact:

Proteome Sciences plc

Dr Jeremy Haigh, Chief Executive Officer

Tel: +44 (0)20 7043 2116

Dr Ian Pike, Chief Scientific Officer

Richard Dennis, Chief Commercial Officer







Allenby Capital Limited (AIM Nominated Adviser & Broker) 

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORZXLFFKXFXBBZ

Quick facts: Proteome Sciences PLC

Price: 3.02

Market: AIM
Market Cap: £8.91 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE